ProShares UltraShort Nasdaq Biotechnology (BIS) is a dynamic exchange-traded fund (ETF) designed for sophisticated investors seeking leveraged inverse exposure to the biotechnology sector within the broader healthcare industry. Specifically focusing on the Pharma, Biotech, & Life Sciences niche, BIS aims to deliver twice the daily inverse performance of the Nasdaq Biotechnology Index. This ETF is particularly suited for those anticipating downturns in the biotech market, offering an opportunity to capitalize on declining stock prices of leading biotechnology companies. By employing a leveraged strategy, ProShares UltraShort Nasdaq Biotechnology provides a potent tool for hedging biotechnology exposure or for those looking to tactically allocate their portfolio with a focus on short-term market movements. Investors should note the inherent volatility and risks associated with leveraged and inverse products, making BIS most appropriate for those with a deep understanding of market dynamics and a keen eye on the biotech sector's trends.
Asset Class
Equity
Region
North America
Issuer
ProShares
Index Tracked
NASDAQ / Biotechnology
Ticker Symbol
BIS
ProShares UltraShort Nasdaq Biotechnology (BIS) Fund Flow Chart
ProShares UltraShort Nasdaq Biotechnology (BIS) 1 year Net Flows: -4M
BIS ETF FAQ
What was BIS’s price range in the past 12 months?
BIS lowest ETF price was 14.05 and its highest was 21.10 in the past 12 months.
What is the AUM of BIS?
As of Jan 28, 2025 The AUM of BIS is 3.33M.
Is BIS overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BIS pay dividends?
BIS pays a Thriceyearly dividend of 0.206 which represents an annual dividend yield of 4.04%. See more information on BIS dividends here
How many shares outstanding does BIS have?
BIS has 201,096 shares outstanding.
Which hedge fund is a major shareholder of BIS?
Currently, no hedge funds are holding shares in BIS